The cardiovascular subtleties of testosterone on gender-affirming hormone therapy
- 1 July 2023
- journal article
- review article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 325 (1) , H30-H53
Abstract
The growing number of people who identify themselves as transgender has gained increased attention in recent years and will certainly impact personalized clinical practices and healthcare worldwide. Transgender and gender-nonconforming individuals frequently undergo gender-affirming hormone therapy (GAHT), i.e., they use sex hormones to align their gender identity with their biological characteristics. Testosterone is the main compound used in GAHT by transmasculine people, leading to the development of male secondary sexual characteristics in these individuals. However, sex hormones, testosterone included, also influence hemodynamic homeostasis, blood pressure, and cardiovascular performance by direct effects in the heart and blood vessels, and by modulating several mechanisms that control cardiovascular function. In pathological conditions and when used in supraphysiological concentrations, testosterone is associated with harmful cardiovascular effects, requiring close attention in its clinical use. The present review summarizes current knowledge on the cardiovascular impact of testosterone in biological females, focusing on aspects of testosterone use by transmasculine people (clinical goals, pharmaceutical formulations, and impact on the cardiovascular system). Potential mechanisms whereby testosterone may increase cardiovascular risk in these individuals are discussed, and the influence of testosterone on the main mechanisms that control blood pressure and that potentially lead to hypertension development and target-organ damage are also reviewed. In addition, current experimental models, which are key to reveal testosterone mechanistic aspects and potential markers of cardiovascular injury, are reviewed. Finally, research limitations and the lack of data on cardiovascular health of transmasculine individuals are considered, and future directions for more appropriate clinical practices are highlighted.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2013/08216-2)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
This publication has 179 references indexed in Scilit:
- Peroxisome proliferator-activated receptor (PPAR)α and -γ regulate IFNγ and IL-17A production by human T cells in a sex-specific wayProceedings of the National Academy of Sciences, 2012
- Transient Exposure of Neonatal Female Mice to Testosterone Abrogates the Sexual Dimorphism of Abdominal Aortic AneurysmsCirculation Research, 2012
- Fetal programming of adult hypertension in female rat offspring exposed to androgens in uteroEarly Human Development, 2011
- Androgen-Dependent Hypertension Is Mediated by 20-Hydroxy-5,8,11,14-Eicosatetraenoic Acid–Induced Vascular DysfunctionHypertension, 2011
- Cardiovascular-Renal and Metabolic Characterization of a Rat Model of Polycystic Ovary SyndromeGender Medicine, 2011
- Chronic anabolic androgenic steroid exposure alters corticotropin releasing factor expression and anxiety-like behaviors in the female mousePsychoneuroendocrinology, 2010
- Aldosterone: A forgotten mediator of the relationship between psychological stress and heart diseaseNeuroscience & Biobehavioral Reviews, 2010
- Sex differences and central protective effect of 17β-estradiol in the development of aldosterone/NaCl-induced hypertensionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Endogenous Melanocortin System Activity Contributes to the Elevated Arterial Pressure in Spontaneously Hypertensive RatsHypertension, 2008
- Altered Expression of Small-Conductance Ca 2+ -Activated K + (SK3) Channels Modulates Arterial Tone and Blood PressureCirculation Research, 2003